EirGenix Signs Licensing and Commercialization Agreement with Japanese Pharmaceutical Company for EG1206A in Japan News News EirGenix Signs Licensing and Commercialization Agreement with Japanese Pharmaceutical Company for EG1206A in Japan EirGenix…
EirGenix Signs Licensing and Commercialization Agreement with Japanese Pharmaceutical Company for EG1206A in Japan
News
EirGenix Signs Licensing and Commercialization Agreement with Japanese Pharmaceutical Company for EG1206A in Japan
[Taipei, June 30] — EirGenix Inc.(TWSE: 6589) has signed a lobal exclusive licensing agreement with Sandoz AG for the commercialization of its independently developed breast cancer biosimilar, EG1206A (Pertuzumab Biosimilar to Roche Perjeta®), covering all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan. Under the terms of the agreement, EirGenix will receive a total up to USD 152 million of upfront and milestone payments. In addition, EirGenix will also be entitled to a profit share once the product is launched in the licensed territory plus potential sales incentives based on market performance. Today, EirGenix announced that it has signed a licensing and commercialization agreement with a leading Japanese pharmaceutical company for EG1206A in Japan.
The Japanese partner is a well-established pharmaceutical company with deep industry expertise, proven execution capabilities, and a strong understanding of Japan’s pharmaceutical environment, which are expected to support the regulatory pathway and commercial launch preparation for EG1206A in Japan. Under the agreement, EirGenix will provide CMC-related know-how and product-related information necessary for regulatory activities, while remaining responsible for product development, manufacturing, and commercial supply. The Japanese partner will lead regulatory approval activities and commercialization in Japan.
Based on the agreement, the project is expected to create potential commercial value of approximately NTD 1.32 billion for EirGenix, including upfront payment, development, regulatory milestones, and profit share after launch. Actual revenue recognition will depend on development progress, regulatory review, launch timing, market performance, and the agreement terms.
EG1206A has completed its pharmacokinetic clinical study and has received positive feedback from both the U.S. Food and Drug Administration and the European Medicines Agency regarding the feasibility of an abbreviated development pathway, including the waiver of Phase III comparative efficacy trials. This agreement marks an important milestone for EirGenix’s biosimilar business and global oncology biosimilar portfolio.
Pertuzumab is an important HER2 targeted therapy for breast cancer. Japan is one of Asia’s major oncology markets, where product quality, regulatory confidence, and stable supply are key considerations for biologic therapies. The evolving HER2-positive breast cancer treatment landscape also continues to support the clinical relevance of pertuzumab-based regimens. As demand for high quality and cost-effective biologic treatment options continues to grow, biosimilars are expected to play an increasingly important role globally. According to Roche’s 2025 annual report, global sales of Perjeta® reached CHF 2.968 billion, approximately NTD 117 billion, and the sales of Perjeta in Japan was CHF 69 million, around NTD 2.7 billion.
EirGenix stated that this agreement is expected to accelerate EG1206A’s development, regulatory submission, and commercialization preparation in Japan. Both parties will advance the program in accordance with Japanese regulatory requirements, with the goal of providing patients with HER2 positive breast cancer greater access to high quality and cost-effective treatment options.
Leveraging its biosimilar development expertise, GMP manufacturing capabilities, and established quality system, EirGenix will continue to advance EG1206A and its broader portfolio, including biosimilar candidates, ADC-related programs, and proprietary subcutaneous formulation technologies. The reference products corresponding to these broader portfolio opportunities represent a sizable global market, with an estimated potential reference market size of USD 50 billion. Through these efforts, EirGenix will continue to expand international collaboration opportunities in biologic life cycle management and oncology therapeutics.
2026-06-30
Back to the previous page
Associated News

2021/07/21

2021/04/06

2021/03/23

2021/03/02

Vstrip® COVID-19 Antigen Rapid Test Validated and Approved in India!
2020/09/26

2020/09/11

2020/07/07

2020/03/09

2020/02/03

2019/06/27

2019/06/10

2019/05/29

2019/04/30

2019/04/10

2019/02/27

2019/01/23

2018/10/30

2018/05/22

2018/05/09
[](https://www.eirgenix.com/data-21328 "EIRGENIX RECEIVED "ASIA'S BEST CMO"")
2018/01/31

2017/11/08
[](https://www.eirgenix.com/data-21331 "EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" BEAM-RAISING CEREMONY")
2017/10/19

2017/05/02
[](https://www.eirgenix.com/data-21333 "EIRGENIX RECEIVED "GRAND WINNER OF BEST BIOPROCESS EXCELLENCE IN TAIWAN"")
2017/02/16
[](https://www.eirgenix.com/data-21335 "EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" GROUNDBREAKING CEREMONY")
2016/12/30

2015/09/24

2014/06/23

2013/12/06

2021/12/08

2021/12/18

2021/12/21

2022/01/26

2020/11/08

2021/10/15

2019/07/10

2022/05/04

2023/09/18

2023/05/01
[ "Gold Award" !")](https://www.eirgenix.com/data-98970 "National Pharmaceutical Technology & Research Development (PTRD) "Gold Award" !")
2023/11/22

2023/11/17

On September 24, EirGenix (6589) announced that it has received positive feedback from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) during scientific consultations regarding the waiver of Phase III clinical trials for its breast cancer biosimilar candidate, EG1206A (Pertuzumab biosimilar). Consequently, the company has officially terminated the on-going Phase III clinical trial for EG1206A. This decision accelerates the global marketing authorization applications (BLA/MAA) for the product and reduces the originally planned product development expenses. Receiving positive feedback from regulatory agencies reflects EirGenix’s long-standing expertise in biosimilar development and marks a significant milestone in the company’s expansion in the biosimilar market.
2025/10/22

2025/11/12
Contact Us
Connect with our team to discuss your biologics development and manufacturing needs.
MORE

TOP
EirGenix, Inc.
EirGenix Inc. Zhubei
EirGenix Europe GmbH
TOP
copyright © 2026 EirGenix, Inc. all rights reserved.
privacy policy
site map